Invizyne Technologies, Inc. (IZTC)
| Market Cap | 100.62M |
| Revenue (ttm) | -700 |
| Net Income (ttm) | -5.12M |
| Shares Out | 9.53M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,211 |
| Open | 10.46 |
| Previous Close | 10.85 |
| Day's Range | 10.40 - 11.40 |
| 52-Week Range | 8.50 - 23.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 15, 2025 |
About IZTC
Invizyne Technologies, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California. [Read more]
Financial Performance
In 2023, Invizyne Technologies's revenue was $70,069, an increase of 145.01% compared to the previous year's $28,598. Losses were -$2.04 million, 46.0% more than in 2022.
Financial StatementsNews
Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
Invizyne Technologies, Inc., a leading designer of enzyme-based biomanufacturing systems – and a...
Invizyne Technologies IPO Registration Document (S-1)
Invizyne Technologies has filed to go public with an IPO on the NASDAQ.
Biomanufacturing company Invizyne Technologies files and sets terms for a $17 million IPO
Invizyne Technologies, which is developing a biomanufacturing platform for a diverse range of chemicals, filed on Friday with the SEC to raise up to $17 million in an initial public offering.